Fiocruz sends Brazilian covid API to the USA for quality tests

30 October 2021

Brazil’s Fiocruz says that production of the active pharmaceutical ingredient (API) for its COVID-19 vaccines is ongoing and is now moving on to a new and important phase of the process.

Two pre-validation batches of the product manufactured by Fiocruz have been approved in all in-house quality tests and are now on their way to an external quality control at US laboratories. At these labs, the samples will go through a complex testing process that involves 14 tests in addition to those carried out in Brazil, the longest of which takes 56 days to complete.

This set of tests compare Brazilian and foreign APIs, ensuring that the product manufactured at the Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz) meets the same quality standards and safety of those acquired by means of Technological Order signed with UK pharma major AstraZeneca (LSE: AZN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK